Imunovir

Inosine Pranobex, the active ingredient in Imunovir, is an immunostimulant presented as an oral formulation for oral use. It is employed to support the immune response in viral infections such as herpes simplex, human papillomavirus, and influenza, and in certain immunodeficiency conditions.

GNH USA supplies Imunovir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from regulatory support and timely delivery across multiple regions.

Imunovir (inosine pranobex) is used as an antiviral immunostimulant in several viral and immunodeficiency conditions.

- Herpes simplex infections: Helps shorten the duration of lesions and reduces viral shedding by stimulating T‑lymphocyte activity and natural killer cell function. - Human papillomavirus infections: Supports clearance of HPV lesions through enhanced cellular immunity, potentially aiding in regression of warts. - Influenza: Contributes to faster symptom resolution and limits viral replication by augmenting the host’s immune defenses. - Immunodeficiency states: Provides adjunctive immune support, improving resistance to opportunistic viral infections in patients with compromised immunity.

Adverse reactions may occur with oral immunostimulants and should be monitored.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Insomnia: difficulty initiating sleep. - Skin rash: mild erythematous eruptions. - Elevated liver enzymes: transient increase in hepatic markers.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling of face or throat. - Hematologic abnormalities: leukopenia or thrombocytopenia requiring medical evaluation.

Patients should be evaluated for underlying conditions and potential risks before initiating therapy. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown excretion; consider alternative therapy. - Liver disease: monitor hepatic function regularly. - Renal impairment: dose adjustment may be required under medical supervision. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Inosine pranobex may interact with other medications that affect immune function or hepatic metabolism.

Major Interactions (Avoid): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may diminish therapeutic effect. - Live vaccines: concurrent use can reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., acyclovir): potential additive toxicity. - Hepatotoxic drugs (e.g., isoniazid): increased risk of liver enzyme elevation. - Anticoagulants (e.g., warfarin): possible alteration of coagulation parameters.